Journal for Immunotherapy of Cancer 2014

1 papers

Top Research Directions

The 2 research directions with Journal for Immunotherapy of Cancer 2014 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Rule Based Dose Escalation and Incremental Titration1100.0%
2The Non-Additive Toxicity of Multi-Modal Adjunctive Therapies1100.0%

Download all directions as CSV

Institutions

Institutions credited by Journal for Immunotherapy of Cancer 2014 papers: a paper credits every institution named in its affiliations, once. 4 institutions share 1 credited papers.

#InstitutionPapersShare
10481e3r23 1100.0%
205bjen692 1100.0%
3National Cancer Institute 1100.0%
4National Institutes of Health 1100.0%

Download all institutions as CSV

About this data

Papers. Journal for Immunotherapy of Cancer 2014 lists 1 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 1 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal for Immunotherapy of Cancer 2014”, https://lacuna.tiptreesystems.com/venue/journal-for-immunotherapy-of-cancer/2014.

Impactful Papers

Papers from Journal for Immunotherapy of Cancer 2014 that shaped research clusters.

Foundational

Papers

Title
Paired tumor biopsy analysis and safety data from a pilot study evaluating Tremelimumab - a monoclonal antibody against CTLA-4 - in combination with ablative therapy in patients with hepatocellular ca